枳术宽中胶囊联合莫沙必利和雷贝拉唑钠治疗反流性食管炎临床疗效及对血清MOT、GAS与炎症因子的影响
|
摘要
[目的]探究枳术宽中胶囊联合莫沙必利和雷贝拉唑钠治疗反流性食管炎临床疗效及对血清胃动素(MOT)、胃泌素(GAS)与炎症因子的影响。[方法]选取2016年6月～2018年5月在我院接受治疗的反流性食管炎患者90例,按随机方法分为对照组和观察组,每组各45例。对照组采用枸橼酸莫沙必利片与雷贝拉唑钠肠溶片治疗。观察组在对照组的基础上口服枳术宽中胶囊治疗,2组患者均连续治疗8周。比较2组治疗临床疗效、临床症状积分、血浆MOT和血清GAS、血清炎症因子及不良反应。[结果]观察组的治疗总有效率明显高于对照组(95.56%:82.22%,P=0.044);治疗后对照组与观察组的临床症状评分均低于治疗前(P<0.05),且同期观察组烧心、反酸与胸骨后疼痛症状评分低于对照组(P<0.05);治疗后2组患者MOT和GAS水平均明显高于治疗前(P<0.05),且观察组治疗后的MOT和血清GAS水平明显高于对照组(P<0.05);治疗后2组患者血清炎症因子含量明显低于治疗前,且观察组治疗后血清炎症因子明显低于对照组(P<0.05)。2组患者不良反应发生率比较差异无统计学意义(P>0.05)。[结论]枳术宽中胶囊联合莫沙必利和雷贝拉唑钠可有效地改善患者临床症状,治疗反流性食管炎疗效显著,值得在临床上推广应用。
[Objective] To investigate the clinical efficacy of Zhizhu Kuanzhong capsules combined with mosapride and rabeprazole sodium in the treatment of reflux esophagitis and its effect on serum levels of MOT, GAS and inflammatory factors. [Methods]90 cases with reflux esophagitis treated in our hospital from June 2016 to May 2018 were selected and randomly divided into two groups, each with 45 cases. The control group received mosapride citrate tablets as well as rabeprazole sodium enteric-coated tablets. Based on the treatment scheme of the control group, the observation group received the Zhizhu Kuanzhong capsules, and both treatments were lasing for 8 wk. The clinical efficacy, clinical symptom score, plasma MOT, serum GAS, serum inflammatory factors and adverse reactions were compared between the two groups. [Results]The total effective rate of the observation group was significantly higher than that of the control group(95.56% vs 82.22%, P=0.044). The clinical symptom scores of Heartburn, acid regurgitation and sternal pain in the two groups after treatment were decreased(P<0.05), and were lower in the observation group than in the control group during the same period(P<0.05). The levels of MOT and GAS in the two groups after treatment were increased(P<0.05), and were higher in the observation group than in the control group(P<0.05). The levels of TNF-α and IL-6 of the two groups after treatment were decreased(P<0.05), and the decrease degree was more significant in the observation group than in the control group(P>0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). [Conclusion]The application of Zhizhu Kuanzhong capsules combined with mosapride and rabeprazole sodium could effectively improve the clinical symptoms of patients with reflux esophagitis, the curative effect is remarkable, which is worthy of clinical application.
[Objective] To investigate the clinical efficacy of Zhizhu Kuanzhong capsules combined with mosapride and rabeprazole sodium in the treatment of reflux esophagitis and its effect on serum levels of MOT, GAS and inflammatory factors. [Methods]90 cases with reflux esophagitis treated in our hospital from June 2016 to May 2018 were selected and randomly divided into two groups, each with 45 cases. The control group received mosapride citrate tablets as well as rabeprazole sodium enteric-coated tablets. Based on the treatment scheme of the control group, the observation group received the Zhizhu Kuanzhong capsules, and both treatments were lasing for 8 wk. The clinical efficacy, clinical symptom score, plasma MOT, serum GAS, serum inflammatory factors and adverse reactions were compared between the two groups. [Results]The total effective rate of the observation group was significantly higher than that of the control group(95.56% vs 82.22%, P=0.044). The clinical symptom scores of Heartburn, acid regurgitation and sternal pain in the two groups after treatment were decreased(P<0.05), and were lower in the observation group than in the control group during the same period(P<0.05). The levels of MOT and GAS in the two groups after treatment were increased(P<0.05), and were higher in the observation group than in the control group(P<0.05). The levels of TNF-α and IL-6 of the two groups after treatment were decreased(P<0.05), and the decrease degree was more significant in the observation group than in the control group(P>0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). [Conclusion]The application of Zhizhu Kuanzhong capsules combined with mosapride and rabeprazole sodium could effectively improve the clinical symptoms of patients with reflux esophagitis, the curative effect is remarkable, which is worthy of clinical application.
引文
[1] Shi ZH,Su W,Zhang JM,et al.Therapeutic effects of Tiaozhong Granule on esophagus mucous membrane in rats with mixed reflux esophagitis and the mechanisms[J].J Integrative Medicine(JIM),2008,6(4):366-366.
[2] Wang XH,Wen H,You SH,et al.An experimental study of using Chai Lai Prescription to treat in vitro rabbit models of reflux esophagitis[J].中华医学杂志(英文版),2013,126(23):4557-4561.
[3] 李美,杨幼新.中医药治疗反流性食管炎研究进展[J].辽宁中医杂志,2016,41(1):197-199.
[4] 中华中医药学会脾胃病分会.胃食管反流病中医诊疗专家共识意见(2017)[J].中国中西医结合消化杂志,2017,25(5):321-326.
[5] 孙传兴.临床疾病诊断依据治愈好转标准[M].第2版.北京:人民军医出版社,1998:71-77.
[6] 唐小波,王亚雷,许建明.胃食管反流病问卷在胃食管反流病诊断中的价值[J].安徽医科大学学报,2011,46(3):275-278.
[7] 朱宝宇,宋德锋,施春雨,等.胃食管反流病发病机制研究进展[J].中国实验诊断学,2015,19(2):344-346.
[8] 楚振荣,李春婷.浅谈胃食管反流病之中医辨证治疗[J].中国临床研究,2015,28(6):817-819.
[9] 徐静,吴攀.枳术宽中胶囊联合兰索拉唑和莫沙必利治疗反流性食管炎的疗效观察[J].现代药物与临床,2016,31(8):1188-1192.
[10] 刘方旭,许乐.枳术宽中胶囊治疗功能性消化不良及抑郁症状疗效及安全性多中心、开放、随机对照研究[J].世界中医药,2012,7(6):484-485.
[11] 安斌,侯光华.枳术宽中胶囊治疗功能性消化不良临床疗效观察[J].辽宁中医药大学学报,2010,12(1):116-117.
[12] 沈雯雯,张玫.枳术宽中胶囊联合质子泵抑制剂和氟哌噻吨美利曲辛治疗非糜烂性胃食管反流病42例[J].河南中医,2015,35(9):2153-2155.
[13] 沈惠贤,张艳霞,赵虹.气滞胃痛颗粒联合莫沙必利治疗反流性食管炎的临床研究[J].现代药物与临床,2018,33(3):555-559.
[14] 赖新兰,杨新魁,刘水清.莫沙必利联合雷贝拉唑钠治疗反流性食管炎的临床研究[J].现代药物与临床,2016,31(10):1538-1541.
[2] Wang XH,Wen H,You SH,et al.An experimental study of using Chai Lai Prescription to treat in vitro rabbit models of reflux esophagitis[J].中华医学杂志(英文版),2013,126(23):4557-4561.
[3] 李美,杨幼新.中医药治疗反流性食管炎研究进展[J].辽宁中医杂志,2016,41(1):197-199.
[4] 中华中医药学会脾胃病分会.胃食管反流病中医诊疗专家共识意见(2017)[J].中国中西医结合消化杂志,2017,25(5):321-326.
[5] 孙传兴.临床疾病诊断依据治愈好转标准[M].第2版.北京:人民军医出版社,1998:71-77.
[6] 唐小波,王亚雷,许建明.胃食管反流病问卷在胃食管反流病诊断中的价值[J].安徽医科大学学报,2011,46(3):275-278.
[7] 朱宝宇,宋德锋,施春雨,等.胃食管反流病发病机制研究进展[J].中国实验诊断学,2015,19(2):344-346.
[8] 楚振荣,李春婷.浅谈胃食管反流病之中医辨证治疗[J].中国临床研究,2015,28(6):817-819.
[9] 徐静,吴攀.枳术宽中胶囊联合兰索拉唑和莫沙必利治疗反流性食管炎的疗效观察[J].现代药物与临床,2016,31(8):1188-1192.
[10] 刘方旭,许乐.枳术宽中胶囊治疗功能性消化不良及抑郁症状疗效及安全性多中心、开放、随机对照研究[J].世界中医药,2012,7(6):484-485.
[11] 安斌,侯光华.枳术宽中胶囊治疗功能性消化不良临床疗效观察[J].辽宁中医药大学学报,2010,12(1):116-117.
[12] 沈雯雯,张玫.枳术宽中胶囊联合质子泵抑制剂和氟哌噻吨美利曲辛治疗非糜烂性胃食管反流病42例[J].河南中医,2015,35(9):2153-2155.
[13] 沈惠贤,张艳霞,赵虹.气滞胃痛颗粒联合莫沙必利治疗反流性食管炎的临床研究[J].现代药物与临床,2018,33(3):555-559.
[14] 赖新兰,杨新魁,刘水清.莫沙必利联合雷贝拉唑钠治疗反流性食管炎的临床研究[J].现代药物与临床,2016,31(10):1538-1541.